NCT04094701 Hip Arthroscopy Postoperative Opioid Demands
| NCT ID | NCT04094701 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rush University Medical Center |
| Condition | Opioid Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 170 participants |
| Start Date | 2020-10-21 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 170 participants in total. It began in 2020-10-21 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be a prospective, single-blinded, randomized controlled trial (RCT), investigating the influence of the number of opioid pills prescribed following primary hip arthroscopy. All patients who sign the consent form will be enrolled in the suited and randomized to one of the two treatment arms. The intervention group will receive 5 Norco pills, gabapentin (30 mg, once daily for 10 days following surgery), and Tylenol (1000 mg, three times daily for 10 days following surgery) while the control will receive the standard at our practice of 30 Norco pills.
Eligibility Criteria
Inclusion Criteria: * Adult patients age 18-80 years * English speaking * Opioid naive patient (defined as not taking opioid pills within 6 weeks prior to surgery), confirmed by checking the Illinois Prescription monitoring program * Primary hip arthroscopy * Written and informed consent for study participation Exclusion Criteria: * Minors (\<18 years of age) * Opioid tolerant patients * Revision surgery * Prior infections of the operative joint * History of active malignancy within the past 5 years * Chronic pain conditions including low back pain, chronic pain syndrome, fibromyalgia * History of alcohol or other substance use disorder * Other disease states including rheumatologic conditions, diabetes mellitus, hypo/hyperthyroidism, depression, anxiety * Grade IV chondral defects
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04094701 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Opioid Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04094701 currently recruiting?
Yes, NCT04094701 is actively recruiting participants. Contact the research team at carla_edwards@rush.edu for enrollment information.
Where is the NCT04094701 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT04094701 clinical trial?
NCT04094701 is sponsored by Rush University Medical Center. The trial plans to enroll 170 participants.